February 2026 A small-molecule inverse agonist of PPARγ for advanced solid tumors: a phase 1 trial VIEW PAPER
February 2026 Updated clinical results and associated biomarkers from an ongoing phase 1 study of FX-909, a first-in-class peroxisome proliferator-activated receptor gamma (PPARG) inhibitor, in patients (pts) with advanced urothelial carcinoma (adv UC) 2026 ASCO Genitourinary Cancers Symposium VIEW SLIDES
November 2025 Phase 1 Clinical Data Show FX-909, a First-in-Class Oral PPARG Inhibitor, Drives Immune Modulation and Pro-Inflammatory Cytokine Induction in IO-Experienced Patients with Advanced Urothelial Carcinoma VIEW POSTER
October 2025 Safety and Clinical Activity of FX-909, a First-in-Class Oral Small Molecule Inhibitor of Peroxisome Proliferator-Activated Receptor Gamma (PPARG), the Master Regulator of Luminal Lineage, in Patients with Advanced Urothelial Carcinoma VIEW POSTER
October 2025 Webinar Presentation of FX-909 Phase 1 Part A Data in Advanced Solid Malignancies Including Advanced Urothelial Carcinoma LISTEN HERE
October 2025 FX-909 Phase 1 Part A Data in Advanced Solid Malignancies Including Advanced Urothelial Carcinoma VIEW SLIDES
February 2025 PPARG Protein Expression in Advanced Urothelial Carcinoma May Provide a Precision Approach to Potentially Select for Response to FX-909, a First-in-Class PPARG-Targeting Agent VIEW POSTER
May 2024 Genomic peroxisome proliferator-activated receptor gamma (PPARG) study: A sponsored testing program to identify patients harboring genetic alterations in advanced UC in support of the FX-909 Phase 1 study AACR Special Conference in Cancer Research: Bladder Cancer: Transforming the Field VIEW POSTER
April 2024 PPARG-High Circulating Monocytes Exhibit An Immunosuppressive Phenotype In Urothelial Cancer Patients Treated with Anti-PD1 American Association for Cancer Research (AACR Annual Meeting) VIEW POSTER
January 2024 A Phase 1, First-in-Human, Dose-Escalation and Expansion Study of FX-909 in Patients with Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma 2024 ASCO Genitourinary Cancers Symposium VIEW POSTER
November 2023 PPARG Amplification is Associated with Lack of Response to Anti-PD1 in Muscle-Invasive Urothelial Cancer Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting VIEW POSTER
October 2023 AI Analysis of Histological Images Accurately Identifies Luminal Subtype Urothelial Carcinomas Characterized by High PPARG Expression 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics VIEW POSTER
April 2023 Development of a surrogate tissue pharmacodynamic (PD) assay for potential clinical use with FX-909, a novel inhibitor of the urothelial luminal lineage transcription factor peroxisome proliferator-activated receptor gamma (PPARG) American Association for Cancer Research (AACR Annual Meeting) VIEW POSTER
October 2022 Novel inhibitors of the luminal lineage transcription factor peroxisome proliferator-activated receptor gamma (PPARG) durably eradicate tumors in urothelial cancer (UC) animal models European Organisation for Research and Treatment of Cancer (34th EORTC-NCI-AACR Symposium) VIEW POSTER
October 2022 Peroxisome proliferator-activated receptor gamma (PPARG) status defines the luminal lineage in molecular profiles of advanced urothelial cancers (UC) European Organisation for Research and Treatment of Cancer (34th EORTC-NCI-AACR Symposium) VIEW POSTER
